Current Neuro-Oncology
Volume
24 Number 20
31 October 2022
Home > Publications > Current Neuro-Oncology > Volume 24, Year 2022 > Number 20, 31 October
Green
S, Vuong VD, Khanna PC, Crawford JR.
Characterization
of pediatric brain tumors using pre-diagnostic neuroimaging.
Front
Oncol. 2022 Oct 17;12:977814∟.
doi: 10.3389/fonc.2022.977814∟.
PMID: 36324580∟.
Observational study. ˍ
Mohamadien
NRA, Diab WA, Abd El-Ghani WMA, Abdelhafez YG.
Posttherapy
technetium-99m pentavalent dimercaptosuccinic acid brain
single-photon emission computed tomography/computed tomography:
diagnostic and prognostic values in patients with glioma.
Nucl
Med Commun. 2022 Oct 17;43(12):1195-1203∟.
doi: 10.1097/MNM.0000000000001623∟.
PMID: 36345764∟.
Observational study˰ ˍ
Romero-Garcia
R, Mandal
AS, Bethlehem RAI, Crespo-Facorro B, Hart MG, Suckling J.
Transcriptomic
and connectomic correlates of differential spatial patterning
among gliomas.
Brain.
2022 Oct 18:awac378∟.
doi: 10.1093/brain/awac378∟.
PMID: 36256589∟.
Laboratory investigation. ˍ
Huang
Y, Ding H, Luo M, Li Z, Li S, Xie C, Zhong Y.
A
new approach to delineating clinical target volume for
radiotherapy of glioblastoma: A phase II trial.
Front
Oncol. 2022 Oct 19;12:931436∟.
doi: 10.3389/fonc.2022.931436∟.
PMID: 36338715∟.
Interventional study. ˍ
*
Slavc
I, Mayr L, Stepien N, Gojo J, Aliotti Lippolis M, Azizi AA,
Chocholous M, Baumgartner A, Hedrich CS, Holm S, Sehested A,
Leblond P, Dieckmann K, Haberler C, Czech T, Kool M, Peyrl
A.
Improved
Long-Term Survival of Patients with Recurrent Medulloblastoma
Treated with a "MEMMAT-like" Metronomic Antiangiogenic
Approach.
Cancers
(Basel). 2022 Oct 19;14(20):5128∟.
doi: 10.3390/cancers14205128∟.
PMID: 36291912∟.
Observational study. ˍ
Tsien
CI, Pugh SL, Dicker AP, Raizer JJ, Matuszak MM, Lallana EC, Huang
J, Algan O, Deb N, Portelance L, Villano JL, Hamm JT, Oh KS, Ali
AN, Kim MM, Lindhorst SM, Mehta MP.
NRG
Oncology/RTOG1205: A Randomized Phase II Trial of Concurrent
Bevacizumab and Reirradiation Versus Bevacizumab Alone as
Treatment for Recurrent Glioblastoma.
J
Clin Oncol. 2022 Oct 19, 2022:JCO2200164∟.
doi: 10.1200/JCO.22.00164∟.
PMID: 36260832∟.
Interventional study˰ ˍ
Veerwal
H, Meena A, Dhingra V.
A
Case of Extracranial Metastasis of Glioblastoma Multiforme Seen on
Bone Scintigraphy.
Mol
Imaging Radionucl Ther. 2022 Oct 19;31(3):246-249∟.
doi: 10.4274/mirt.galenos.2021.09815∟.
PMID: 36268939∟.
Case report. ˍ
Le Rhun E, Oppong FB, van den
Bent M, Wick W, Brandes AA, Taphoorn MJ, Platten M, Idbaih A,
Clement PM, Preusser M, Golfinopoulos V, Gorlia T, Weller
M.
Thrombocytopenia
limits the feasibility of salvage lomustine chemotherapy in
recurrent glioblastoma: a secondary analysis of EORTC 26101.
Eur
J Cancer. 2022 Oct 20,
2023;178:13-22∟.
doi: 10.1016/j.ejca.2022.10.006∟.
PMID: 36379185∟.
Observational study. ˍ
*
Liu
K, Liao X, Chen Y, Jiang S.
Adjuvant
Chemoradiation therapy Versus Chemotherapy Alone for Resected
Oligodendroglioma: A Surveillance, Epidemiology and End Results
(SEER) Analysis.
World
Neurosurg. 2022 Oct 20, 2022:S1878-8750(22)01480-2∟.
doi: 10.1016/j.wneu.2022.10.063∟.
PMID: 36273731∟.
Observational study. ˍ
Yang
F, Dinakaran D, Heikal AA, Yaghoobpour Tari S, Ghosh S, Amanie J,
Murtha A, Rowe LS, Roa W, Patel S.
Dosimetric
Predictors Of Toxicity In A Randomized Study Of Short-Course Vs.
Conventional Radiotherapy For Glioblastoma.
Radiother
Oncol. 2022 Oct 20, 2022:S0167-8140(22)04510-8∟.
doi: 10.1016/j.radonc.2022.10.016∟.
PMID: 36273738∟.
Interventional study˰ ˍ
Panda
PK, Gupta T, Jalali R.
A
Practice Pilot Survey on the Current Use of Corticosteroid Therapy
in Brain Tumor Patients.
Neurol
India. 2022 Oct 21;70(5):1896-1900∟.
doi: 10.4103/0028-3886.359216∟.
PMID: 36352584∟.
Observational study. ˍ
Yang
DY, Cheng X, Bu XY, Yan ZY, Qu MQ, Zhao YW, Kong LF, Wang YW, Luo
JC.
Granulocyte-macrophage
colony stimulating factor enhances efficacy of nimustine
rendezvousing with temozolomide plus irradiation in patients with
glioblastoma.
Technol
Health Care. 2022 Oct 21∟.
doi: 10.3233/THC-220194∟.
PMID: 36314174∟.
Observational study˰ ˍ
Yi
GZ, Zhu TC, Que TS, Li ZY, Huang GL.
Individualized
combination therapies based on whole-exome sequencing displayed
significant clinical benefits in a glioblastoma patient with
secondary osteosarcoma: case report and genetic
characterization.
BMC
Neurol. 2022 Oct 21;22(1):390∟.
doi: 10.1186/s12883-022-02920-x∟.
PMID: 36271359∟.
Case report. ˍ
Battista
F, Muscas G, Dinoi F, Gadda D, Della Puppa A.
Ventricular
entry during surgical resection is associated with intracranial
leptomeningeal dissemination in glioblastoma patients.
J
Neurooncol. 2022 Oct 23∟.
doi: 10.1007/s11060-022-04166-6∟.
PMID: 36273377∟.
Observational study. ˍ
Yamaki
T, Higuchi Y, Yokota H, Iwadate Y, Matsutani T, Hirono S, Sasaki
H, Sasao R, Toda M, Onodera S, Oka N, Kobayashi S.
The
role of optimal cut-off diagnosis in 11C-methionine PET for
differentiation of intracranial brain tumor from non-neoplastic
lesions before treatment.
Clin
Imaging. 2022 Oct 24;92:124-130∟.
doi: 10.1016/j.clinimag.2022.10.007∟.
PMID: 36374712∟.
Observational study˰ ˍ
Immisch
L, Papafotiou G, Popp O, Mertins P, Blankenstein T, Willimsky
G.
H3.3K27M
mutation is not a suitable target for immunotherapy in HLA-A2+
patients
with diffuse midline glioma.
J
Immunother Cancer. 2022 Oct 27;10(10):e005535∟.
doi: 10.1136/jitc-2022-005535∟.
PMID: 36302563∟.
Laboratory investigation. ˍ
Mueller
T, Laternser S, Guerreiro Stücklin AS, Gerber NU, Mourabit S,
Rizo M, Rushing EJ, Kottke R, Grotzer M, Krayenbühl N,
Nazarian J, Mueller S.
Real-time
drug testing of paediatric diffuse midline glioma to support
clinical decision making: The Zurich DIPG/DMG centre
experience.
Eur
J Cancer. 2022 Oct 28, 2023;178:171-179∟.
doi: 10.1016/j.ejca.2022.10.014∟.
PMID: 36455411∟.
Observational study˰ ˍ
Sharma
A, Das AK, Jain A, Purohit DK, Solanki RK, Gupta A.
Study
of Association of Various Psychiatric Disorders in Brain
Tumors.
Asian
J Neurosurg. 2022 Oct 28;17(4):621-630∟.
doi: 10.1055/s-0042-1757437∟.
PMID: 36570750∟.
Observational study. ˍ
Vieito M, Simonelli M, de Vos F,
Moreno V, Geurts M, Lorenzi E, Macchini M, van den Bent MJ, Del
Conte G, de Jonge M, Martín-Soberón MC, Amoroso B,
Sanchez-Perez T, Zuraek M, Hanna B, Aronchik I, Filvaroff E, Chang
H, Mendez C, Arias Parro M, Wei X, Nikolova Z, Sepulveda
JM.
Trotabresib
(CC-90010) in combination with adjuvant temozolomide or
concomitant temozolomide plus radiotherapy in patients with newly
diagnosed glioblastoma.
Neurooncol
Adv. 2022 Oct 28;4(1):vdac146∟.
doi: 10.1093/noajnl/vdac146∟.
PMID: 36382109∟.
Interventional study. ˍ
Yang
K, Ma Y, Chen G, Zeng S, Guo T, Yang Z.
Comparative
analysis of the prognosis of external beam radiation therapy
(EBRT) and EBRT plus brachytherapy for glioblastoma multiforme: a
SEER population-based study.
Radiat
Oncol. 2022 Oct 28;17(1):174∟.
doi: 10.1186/s13014-022-02141-z∟.
PMID: 36307810∟.
Observational study. ˍ
Rudà
R, Bruno F, Pellerino A, Pronello E, Palmiero R, Bertero L, Crasto
S, Polo V, Vitaliani R, Trincia E, Internò V, Porta C,
Soffietti R.
Observational
real-life study on regorafenib in recurrent glioblastoma: does
dose reduction reduce toxicity while maintaining the efficacy?
J
Neurooncol. 2022 Oct 30∟.
doi: 10.1007/s11060-022-04155-9∟.
PMID: 36309895∟.
Observational study˰ ˍ
Șerban
G, Tămaș F, Bălașa R, Manu D, Tămaș
C, Bălașa A.
Prognostic
Factors of Survival in Glioblastoma Multiforme Patients-A
Retrospective Study.
Diagnostics
(Basel). 2022 Oct 30;12(11):2630∟.
doi: 10.3390/diagnostics12112630∟.
PMID: 36359474∟.
Observational study. ˍ
Greenwell
AM, Baughan S, Altinok D, Marupudi NI, Kupsky W, Kumar-Sinha C,
Gorsi HS.
Lorlatinib
for the Treatment of ALK Fusion-Positive Infant-Type Hemispheric
Glioma: A Case Report.
JCO
Precis Oncol. 2022 Oct 31;6:e2200255∟.
doi: 10.1200/PO.22.00255∟.
PMID: 36315913∟.
Case report˰ ˍ